Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

My take on the next conference call:
1) The will do a chest-thumping for partnering HER-2 with OST. No details of the partnership will be disclosed, however.
2) We will see no milestone payments from Amgen with regards to NEO (I am making this assumption based on the preliminary Q2 financial results).
3) They will re-iterate that they continue to sell/partner AXAL for cervical. No more details, but it's more likely they are preparing themselves for shelving the Aim2Cerv and paying the penalties (thus the paragraph about where the new cash is going, per recent 8-K).
4) HOT likely to start by the end of 2018, but dosing of the 1st patient early 2019. They say they are not partnering this NSCLC program now. Rather, they'd wait for the data from Ph1 and then sell/partner. They supposedly have cash to complete Ph1 for HOT.
5) Rehash ADXS/PSA trials, and may have some update. Reiterate that Merck is still interested.

As the closing of this secondary is tomorrow, we may get some update on who purchased these shares. No more b.s. about "you'd be very happy to see the list of the 2ndary buyers" from Noelle automata.
@wmtgreeter
#sellthebeech4sixbillions